SOCMA Issues Statement to US Senate Subcommittee on TSCA Reform - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Issues Statement to US Senate Subcommittee on TSCA Reform

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA), in a statement submitted to the US Senate Subcommittee on Superfund, Toxic and Environmental Health, provided support for a bipartisan review of the Toxic Substances Control Act (TSCA) as that subcommittee considers reforming the  chemical-control law. SOCMA is a trade association representing custom and batch manufacturers, including contract manufacturers of active pharmaceutical ingredients, pharmaceutical intermediates, and other fine and specialty chemicals.

“SOCMA understands that TSCA modernization is a complex issue that deserves close scrutiny,” said SOCMA President Lawrence D. Sloan in a SOCMA Feb. 3, 2011, press release. “Many relevant factors should be considered, most of which, we believe, fall outside the statute itself.”

Sloan said that TSCA's critics selectively cite chemical statistics that paint an incomplete picture of TSCA’s effectiveness. He underscored the fact that these statistics alone make it appear as if TSCA has failed due to a relatively low number of restricted chemicals, but contended that a great deal of testing is conducted. He added that most chemicals can be used safely and therefore do not require additional restrictions. Sloan noted that there are many other federal laws that govern chemicals management and that advances in the field of analytical chemistry should be acknowledged before “placing  blame solely on TSCA for increased exposures,” according to the SOCMA release.

SOCMA asked the subcommittee to consider various metrics to evaluate TSCA before introducing new legislation, such as the following:

  • The number of new chemicals reviewed by the Environmental Protection Agency under Section 5 since TSCA’s inception
  • The number of Pre-Manufacturing Notices (PMN) that were withdrawn as a result of those reviews
  • The number of PMNs for which review periods were voluntarily suspended while the submitter conducted tests or gathered other data
  • The number of Significant New Use Rules (SNURs) issued by EPA
  • The number of existing chemicals actually in commerce.

“Ultimately, success will not depend solely or primarily on how many chemicals are restricted, but on the net health, environmental, and economic effects of implementing these laws,” Sloan said in the release.

SOCMA said it will continue its efforts to promote recommendations for a “pragmatic approach” to TSCA modernization with members of Congress. On Apr. 13, 2011, SOCMA members will discuss their position with lawmakers and their staff during the association’s annual Washington Fly-In.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here